Format

Send to

Choose Destination
Dig Dis Sci. 2016 Oct;61(10):2823-2830. doi: 10.1007/s10620-016-4219-x. Epub 2016 Jul 14.

Direct Costs in Patients with Celiac Disease in the USA: A Retrospective Claims Analysis.

Author information

1
University of Chicago, 5721 S. Maryland Avenue, Chicago, IL, 60637, USA. sguandalini@peds.bsd.uchicago.edu.
2
AbbVie Inc., 1 N Waukegan Road, North Chicago, IL, 60064, USA.
3
Analysis Group, 10 Rockefeller Plaza, 15th Floor, New York, NY, 10020, USA.
4
Alvine Pharmaceuticals, 75 Shoreway Road, Suite B, San Carlos, CA, 94070, USA.

Abstract

BACKGROUND:

Celiac disease (CeD) is an autoimmune disease triggered by gluten ingestion.

AIM:

We assessed total direct costs burden associated with CeD in patients with CeD versus patients without CeD using administrative claims data.

METHODS:

Patients with CeD (cases) with ≥1 occurrences of CeD diagnosis were selected at a randomly chosen date (index date) from the OptumHealth Reporting and Insights database from 01/01/1998 through 03/31/2013. Cases were continuously enrolled throughout baseline (1 year before index date) and study (1 year after index date) periods. Cases were categorized as full remission and partial remission and matched 1:1 based on age, sex, region, index date, company, and employment status. Total all-cause and CeD-related costs were calculated.

RESULTS:

A total of 12,187 cases were matched with an equal number of controls. Mean total all-cause costs were $12,217 in cases versus $4935 in controls (P < 0.0001). In full remission (N = 10,181 [83.5 %]) and partial remission (N = 2006 [16.5 %]) cases, mean total all-cause direct costs (cases versus controls) were $11,038 versus $4962 and $18,206 versus $4796, respectively. All-cause medical costs ($9839 for all cases, $8723 for full remission cases, $15,499 for partial remission cases) accounted for the majority of all-cause total costs and included outpatient costs ($6675; $6456; and $7785, respectively) and hospitalizations ($2776; $1963; and $6906, respectively). CeD-related medical costs were 13 and 27 % of all-cause medical costs for all cases and partial remission cases, respectively.

CONCLUSIONS:

Patients with CeD and partial remission of CeD incurred significantly higher (2.5 and 3.8 times) total all-cause costs compared with matched controls.

KEYWORDS:

Celiac disease; Economic burden of disease; Gluten-sensitive enteropathy; Health care costs

PMID:
27417565
DOI:
10.1007/s10620-016-4219-x
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center